Please ensure Javascript is enabled for purposes of website accessibility

Why GenMark Stock Soared Today

By Joe Tenebruso - Mar 15, 2021 at 9:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A healthcare titan is acquiring the diagnostic-test maker for a hefty premium.

What happened

Shares of GenMark Diagnostics (GNMK) surged 29.6% on Monday after the molecular testing company said it has agreed to a merger with Swiss pharmaceutical giant Roche Holding (RHHBY 1.82%)

So what

Roche will conduct a tender offer to acquire all of GenMark's outstanding stock for $24.05 per share, a roughly 43% premium to the price at which its shares were trading before rumors of the merger emerged back in February. The all-cash deal values GenMark at roughly $1.8 billion. It's expected to close in the second quarter.

Two people are shaking hands.

GenMark and Roche agreed to a merger on Monday. Image source: Getty Images.

GenMark's diagnostic tests are designed to detect multiple pathogens from a single patient sample. Its ePlex system helps to make laboratories more efficient via streamlined workflows, and its fast test results can help clinicians rapidly determine the causes of their patients' infections.

"Acquiring GenMark Diagnostics will broaden our molecular diagnostics portfolio to include solutions that can provide lifesaving information quickly to patients and their healthcare providers in the fight against infectious diseases," Roche CEO Thomas Schinecker said in a press release.

Now what

Roche will use its global distribution network to accelerate the rollout of GenMark's products. In the process, it intends to increase GenMark's share of a molecular testing market that could grow to $2 billion by 2024, according to Schinecker. And by providing doctors with better tools to combat infectious diseases, the combined company could help to save countless lives.

"Together with Roche's diagnostics healthcare solutions, we will be able to provide a full suite of molecular diagnostic solutions to customers around the world," GenMark CEO Scott Mendel said.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GenMark Diagnostics, Inc. Stock Quote
GenMark Diagnostics, Inc.
Roche Holding AG Stock Quote
Roche Holding AG
$41.86 (1.82%) $0.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.